1-(3,3,4,4,4-Pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidohydrazide | 1403745-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1-(3,3,4,4,4-Pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidohydrazide
• 英文别名: N'-amino-1-(3,3,4,4,4-pentafluorobutyl)pyrazolo[3,4-b]pyridine-3-carboximidamide
• CAS: 1403745-15-2
• 化学式: C₁₁H₁₁F₅N₆
• 分子量: 322.241
• InChiKey: LTIIMMOXZAVDTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  dimethyl 2,2-dimethyl-3-oxobutanedioate 、 1-(3,3,4,4,4-Pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidohydrazide 以 乙醚 、 乙醇 为溶剂， 以50%的产率得到Methyl 2-{5-hydroxy-3-[1-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-1,2,4-triazin-6-yl}-2-methylpropanoate
  参考文献：
  名称：

  FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF

  摘要：

  本申请涉及新颖的氟烷基取代的吡唑吡啶类化合物，以及它们的制备方法，它们的单独或组合使用用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。

  公开号：

  US20140100229A1
• 作为产物：
  描述：

  1-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide hydrochloride 在 一水合肼 、 三乙胺 作用下， 以 乙醇 为溶剂， 以77 mg的产率得到1-(3,3,4,4,4-Pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidohydrazide
  参考文献：
  名称：

  [EN] SGC STIMULATORS
  [FR] STIMULATEURS DE SGC

  摘要：

  公开号：

  WO2018089330A8

文献信息

• Fluoroalkyl-substituted pyrazolopyridines and use thereof
  申请人：Follmann Markus

  公开号：US09090610B2

  公开（公告）日：2015-07-28

  The present application relates to novel fluoroalkyl-substituted pyrazolopyridines, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

  本发明涉及一种新型的含氟烷基取代的吡唑吡啶，其制备方法、其用于单独或组合治疗和/或预防疾病的用途以及用于生产治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病的用途。
• SGC stimulators
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US11180493B2

  公开（公告）日：2021-11-23

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

  本公开涉及可溶性鸟苷酸环化酶（sGC）的刺激剂、包含它们的药物制剂及其单独或与一种或多种附加制剂组合的用途，用于治疗各种疾病，其中一氧化氮（NO）浓度的增加和/或环磷酸鸟苷（cGMP）浓度的增加可能是可取的。本文公开了多种化合物，包括式（I）化合物。
• FLUORALKYL-SUBSTITUIERTE PYRAZOLOPYRIDINE UND IHRE VERWENDUNG
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2699578A1

  公开（公告）日：2014-02-26
• SGC STIMULATORS
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US20200071318A1

  公开（公告）日：2020-03-05

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).
• sGC STIMULATORS
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US20220017515A1

  公开（公告）日：2022-01-20

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I: